Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

dpp-4 inhibitor compound

A compound, n-b- technology, applied in the field of DPP-4-related diseases, dipeptidyl peptidase IV (DPP-4) inhibitor compounds, can solve the problem of GLP-1 inactivation and so on

Active Publication Date: 2015-08-05
NANJING HUAWE MEDICINE TECH DEV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, DPP-4 can rapidly cleave proline or alanine at the second position of the N-terminal of the GLP-1 peptide chain in vivo, resulting in the inactivation of GLP-1

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • dpp-4 inhibitor compound
  • dpp-4 inhibitor compound
  • dpp-4 inhibitor compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073]

[0074] experiment procedure:

[0075] first step:

[0076] Method A

[0077] Weigh Boc-(R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid (1.0g, 3.0mmol), anhydrous piperazine (0.26g, 3.0mmol), HBTU ( 2.27g, 6.0mmol) was added into a 100ml round bottom flask, dissolved in 20ml of DMF, then DIEA (0.78g, 6.0mmol) was added to the reaction solution, and stirred at room temperature for 1.5 hours. TLC detection (petroleum ether: ethyl acetate = 4:1), the reaction was completed, the reaction solution was added to 10 times the amount of water, a white solid was precipitated, filtered, the filter cake was washed with water, and the obtained solid was dried.

[0078] Method B

[0079] Weigh Boc-(R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid (1.0g, 3.0mmol), anhydrous piperazine (0.26g, 3.0mmol), DCC ( 6.0mmol) and HoBt (6.0mmol) were added to a 100ml round bottom flask, dissolved with 20ml DMF, then DIEA (12.0mmol) was added to the reaction solution, and stirred at ...

Embodiment 2

[0085] Chemical reaction formula:

[0086]

[0087] Experimental process: The specific experimental process of compound 2 is similar to that of Example 1, refer to Example 1.

[0088] MSm / z (ESI):613.5[M+Na]

[0089] 1 H-NMR (500MHz, deuterated DMSO): δ7.31~7.38(m, 2H), 7.13~7.22(m, 2H), 4.01~4.15(m, 2H), 4.42(m,1H), 3.67(s ,3H), 2.80~2.91(m.4H), 2.59~2.72(m,4H).

Embodiment 3

[0091] Chemical reaction formula:

[0092]

[0093] Experimental process: The specific experimental process of compound 3 is similar to that of Example 1, refer to Example 1.

[0094] MSm / z(ESI):539.3[M+H]

[0095] 1 H-NMR (500MHz, deuterated DMSO): δ7.60~7.65(m, 4H), 7.31~7.38(m, 2H), 7.13~7.22(m, 2H), 4.42(m, 1H), 4.01~4.15 (m, 2H), , 3.67 (s, 3H), 2.80~2.91 (m.4H), 2.59~2.72 (m, 4H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a novel dipeptidyl peptidase IV (DPP-4) inhibitor compound as shown in Formula (I) as shown in the specification. The compound, optical isomers, pharmaceutically acceptable inorganic or organic salt, crystal forms, hydrates or solvates of the compound can be used for treating diabetes, particularly non-insulin dependent diabetes, and other diseases related to DPP-4. Definitions of substituents in the general formula (I) are the same as those in the specification.

Description

technical field [0001] The invention belongs to the field of organic synthesis, and specifically relates to a novel dipeptidyl peptidase IV (DPP-4) inhibitor compound and its application for treating and preventing diabetes and other diseases related to DPP-4. Background technique [0002] Diabetes is a chronic metabolic disease caused by various pathogenic factors such as genetic factors, immune dysfunction, microbial infection and its toxins, free radical toxins, and mental factors. Clinically, it is characterized by hyperglycemia. It can be divided into type 1 diabetes (insulin-dependent), type 2 diabetes (non-insulin-dependent), gestational diabetes and other special types of diabetes. Type 2 diabetes accounts for approximately 95% of diabetic patients. [0003] At present, the main oral hypoglycemic drugs are: sulfonylureas (SU), biguanides, α-glucosidase inhibitors, non-sulfonylurea insulin secretory drugs and insulin sensitizers: thiazolidinediones. These drugs are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D295/185C07C237/20C07D487/04C07D207/08C07C229/34C07D241/04C07D241/42C07C255/29C07C231/12C07C227/20C07C253/30A61K31/495A61K31/216A61K31/167A61K31/165A61K31/407A61K31/40A61K31/498A61K31/277A61P3/10
CPCC07C229/34C07C237/20C07C255/29C07C2601/14C07D207/08C07D241/04C07D241/42C07D295/192C07D487/04
Inventor 张孝清宋志春包金远蒋玉伟
Owner NANJING HUAWE MEDICINE TECH DEV
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com